Diffusion capacity of the lung for carbon monoxide (DLCO) >= % of predicted (corrected or uncorrected for hemoglobin per institutional standards)
Patients must have pulmonary function sufficient to receive bleomycin, with normal lung expansion, absence of crackles on auscultation, and normal carbon monoxide diffusion (DLCO), defined as greater than % predicted
Documented diffusion capacity of the lung for carbon monoxide (DLCO) < % (if performed within  days of enrollment) or requirement for supplemental oxygen
Pulmonary: Asymptomatic or if symptomatic, diffusion capacity of the lung for carbon monoxide (DLCO) > % of predicted (corrected for hemoglobin).
Pulmonary function (spirometry and corrected diffusion capacity of the lung for carbon monoxide [DLCO]) >= % predicted.
Corrected diffusion capacity of the lung for carbon monoxide (DLCOc) >= %;
Diffusion capacity > % (adjusted for hemoglobin) as predicted by pulmonary function testing
Within  weeks before enrollment: Diffusion capacity > % (adjusted for hemoglobin) as predicted pulmonary function testing
Pulse oximetry with a baseline O saturation of >= % and diffusion capacity of the lung for carbon monoxide (DLCO) > % (corrected for hemoglobin)
Pulmonary function tests within past  months showing diffusion capacity of the lung for carbon monoxide (DLCO) > % of predicted
Pulmonary function test (PFT) demonstrating a diffusion capacity of least % predicted.
Diffusion capacity of the lung for carbon monoxide (DLCO) > %
DLCO =< %
Diffusion capacity of the lung for carbon monoxide (DLCO) < % of normal or oxygen saturation (O Sat) < %
Diffusion capacity of the lungs for carbon monoxide (DLCO) (corrected for hemoglobin [Hgb]) >= %
If measured, carbon monoxide diffusion capacity (DLCO) > %
Other serious medical conditions considered to represent contraindications to bone marrow transplant (BMT) (e.g., abnormally decreased cardiac ejection fraction, diffusion capacity of the lung for carbon monoxide [DLCO] < % predicted, patient on supplemental oxygen, acquired immune deficiency syndrome [AIDS], etc.)
Adequate cardiac and pulmonary function; patients with decreased left ventricular ejection fraction (LVEF) =< % or diffusion capacity of carbon monoxide (DLCO) =< % of predicted will be evaluated by cardiology or pulmonary prior to enrollment on this protocol; patient with left ventricular assist device (LVAD) placement without heart failure symptoms will be allowed
Diffusion capacity of the lung for carbon monoxide (DLCO) < %
Diffusion capacity of carbon monoxide (DLCO) < % predicted (corrected for hemoglobin and alveolar volume)
DLCO (alveolar diffusion capacity for carbon monoxide) (corrected for hemoglobin) >= % of predicted
Diffusion capacity of the lung for carbon monoxide (DLCO) > %
Patients requiring supplementary continuous oxygen and/or diffusion capacity of the lung of carbon monoxide (DLCO) < %
Diffusion lung capacity of oxygen (DLCO) >= % of predicted corrected for hemoglobin
Pulmonary function test (PFT) demonstrating a diffusion capacity of least % predicted
Corrected diffusion capacity of the lung for carbon monoxide (DLCO) >= %
For all patients: diffusion capacity of the lungs for carbon monoxide (DLCO) > % predicted (corrected for hemoglobin [Hgb])
Adequate pulmonary function with corrected diffusion capacity of carbon monoxide (DLCO) > % in those for whom this study can be performed
Pulmonary: asymptomatic or if symptomatic, diffusion capacity of the lung for carbon monoxide (DLCO) >= % of predicted (corrected for hemoglobin)
Corrected diffusion capacity of the lung for carbon monoxide (DLCO) >= %
Adequate pulmonary function defined as diffusion capacity of carbon monoxide (DLCO) > % predicted, and absence of oxygen (O) requirements
Patients must have no significant obstructive airways disease or resting hypoxemia (partial pressure of oxygen [PO] < ), and must have acceptable diffusion capacity (diffusion capacity of the lung for carbon monoxide [DLCO] > % of predicted)
Pulmonary function test and diffusion capacity of carbon monoxide (DLCO) > % of normal
Diffusion capacity of carbon monoxide (DLCO)corr > % normal
Diffusion capacity of oxygen, corrected for hemoglobin, > % of predicted
Pulmonary function test (PFT) demonstrating a diffusion capacity of least % predicted
DLCO > %
Diffusion capacity of the lung for carbon monoxide (DLCO) > % with no symptomatic pulmonary disease
Pulmonary function (diffusion capacity of the lung for carbon monoxide [DLCO]) > % of the expected value corrected for alveolar volume and hemoglobin
Pulmonary disease: diffusion capacity of the lung for carbon monoxide (DLCO) parameters < % predicted (corrected for hemoglobin)
Lung diffusion capacity >= %
Spirometry diffusion capacity (diffusion capacity of the lung for carbon monoxide [DLCO]) >= %
Diffusion capacity of carbon monoxide (DLCO) >= % predicted, no oxygen (O) requirements
Other serious medical conditions considered to represent contraindications to ASCT (e.g., abnormally decreased cardiac ejection fraction, diffusion capacity of the lung for carbon monoxide [DLCO] < % predicted, acquired immune deficiency syndrome [AIDS], etc.)
Patients with a diffusion capacity of the lung for carbon monoxide (DLCO) < % of normal or
Corrected diffusion capacity of the lung for carbon monoxide (DLCO) > % of expected value
Respiratory compromise, defined as ventilation tests with diffusion capacity of the lung for carbon monoxide (DLCO) < %
Diffusion lung capacity for carbon monoxide (DLCO) adjusted for hemoglobin >= % predicted, except if related to high volume metastatic GCT to the lungs, in which case there is no minimum DLCO requirement; in some cases, patients may not be able to undergo pulmonary function test (PFT) testing due to the severity of their presentation, such as those with high volume lung metastases or tumor-related pain (from large mediastinal masses, pleural disease, etc.) limiting their ability to complete PFTs; even when PFTs can be completed in these cases, patients will still be eligible if the low DLCO can be attributed directly to the patient's disease (e.g. large mediastinal mass) rather than intrinsic lung disease; since there is no minimum DLCO for these patients, under these extraordinary circumstances, this will be allowed; most patients in this situation will be expected to receive disease-stabilizing chemotherapy; an unadjusted DLCO may be used in place of the DLCO adjusted for hemoglobin in certain situations as per institutional policy; for example, MSKCC policy is to not adjust the DLCO for hemoglobin when the hemoglobin is >= . g/dL for males and >= . g/dL for females; in these cases, the unadjusted DLCO must be >= % predicted
Idiopathic interstitial pneumonia or impaired diffusion capacity of the lung for carbon monoxide (DLCO).
Other serious medical conditions considered to represent contraindications to ASCT (e.g., abnormally decreased cardiac ejection fraction, diffusion capacity of carbon monoxide [DLCO] < % predicted, etc.)
Pulmonary diffusion capacity > % lower than normal predicted value
Patients with significant, symptomatic deterioration of lung function confirmed by spirometry, diffusion capacity of the lungs for carbon monoxide (DLCO), or resting oxygen (O) saturation
Corrected pulmonary diffusion capacity of greater than or equal to %
Adequate pulmonary function as assessed by diffusion capacity of the lung for carbon monoxide (DLCO) of >= % adjusted for hemoglobin
Subjects with asymptomatic pulmonary function based on lung diffusion testing diffusion capacity of the lung for carbon monoxide (DLCO) test; DLCO >= % of predicted (corrected for hemoglobin)
Diffusion capacity of the lung for carbon monoxide (DLCO) >= % predicted within  weeks prior to study enrollment; no oxygen (O) requirements
Pulmonary: asymptomatic or if symptomatic, diffusion lung capacity of carbon monoxide (DLCO) > % of predicted (corrected for hemoglobin)
Diffusion lung capacity of carbon monoxide (DLCO) < % predicted
Corrected diffusion lung capacity of carbon monoxide (DLCO) < % or receiving supplemental continuous oxygen
Pulmonary: asymptomatic or if symptomatic, diffusion capacity of carbon monoxide (DLCO) > % of predicted (corrected for hemoglobin)
Subjects with clinical signs of pulmonary insufficiency must have diffusion capacity of the lung for carbon monoxide (DLCO) to be measured at >= % of predicted value
Patients with active pulmonary infection and/or pulse oximetry < % and a corrected diffusion capacity of the lung for carbon monoxide (DLCO) < % of predicted
Corrected diffusion capacity of carbon monoxide (DLCO) < % and/or receiving supplemental continuous oxygen
Diffusion capacity of the lung for carbon monoxide (DLCO) > % of the expected value when corrected for hemoglobin (Hb), obtained within  days of enrollment
Pulmonary function tests as follows: diffusion capacity of the lungs for carbon monoxide (DLCO) > % predicted
Corrected diffusion capacity of the lung for carbon monoxide (DLCO) equal or above % of expected
Subjects >  years: DLCO (diffusion capacity) > % of predicted (corrected for hemoglobin)
Pulmonary function test (PFT) demonstrating a diffusion capacity of least % predicted, corrected for hemoglobin
Diffusion capacity of the lung for carbon monoxide (DLCO) < % predicted (post-bronchodilator)
Patients with prior smoking history or emphysema will require diffusion lung capacity for carbon monoxide (DLCO) of >= % of predicted value for age
Diffusion capacity of carbon monoxide (DLco) <% of predicted (corrected for hemoglobin).
Adjusted diffusion capacity of the lung for carbon monoxide (DLCO) < %
Corrected diffusion capacity of the lung for carbon monoxide (DLCO) >= % by pulmonary function test